{"id":"NCT00091572","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)","officialTitle":"Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10-20","primaryCompletion":"2007-12-31","completion":"2007-12-31","firstPosted":"2004-09-14","resultsPosted":"2009-03-12","lastUpdate":"2017-06-06"},"enrollment":859,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"Temozolomide","otherNames":["Temodal, Temodar, SCH 52365"]},{"type":"DRUG","name":"Dacarbazine","otherNames":["DTIC-Dome"]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma than single agent dacarbazine.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"The final analysis was to be performed when at least 616 deaths had occurred.","effectByArm":[{"arm":"Temozolomide","deltaMin":9.13,"sd":null},{"arm":"Dacarbazine","deltaMin":9.36,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9999"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21600759"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":124,"n":419},"commonTop":["FATIGUE","NAUSEA","VOMITING","CONSTIPATION","ANOREXIA"]}}